文献速递免疫规划传染病防控与疫情报告

Hantavax®疫苗3+1剂次程序在健康成人中的免疫原性与安全性:多中心III期临床试验

Immunogenicity and safety of a modified three-dose priming and booster schedule for the Hantaan virus vaccine (Hantavax): A multi-center phase III clinical trial in healthy adults.
PubMed 文献 · Vaccine · 2020-10-31

该III期多中心试验在320名≥19岁健康成人中评估Hantavax®按0、1、2、13月程序接种的免疫原性与安全性。基础三剂后PRNT和IFA血清阳转率分别为80.97%和92.81%;加强后一个月PRNT和IFA血清阳性率分别为67.47%和95.68%。局部和全身不良事件未随接种次数增加而升高。

要点

  • 基础三剂后PRNT血清阳转率80.97%,IFA为92.81%。
  • 加强后一个月PRNT血清阳性率67.47%,IFA为95.68%。
  • 局部和全身不良事件未随重复接种增加。

核心结论

  • Hantavax®基础三剂后血清阳转率高,间隔11个月加强可诱导良好加强效果。

研究设计与样本

  • III期多中心临床试验,纳入320名≥19岁健康成人,按0、1、2、13月接种三剂基础加一剂加强。
  • 采用蚀斑减少中和抗体试验(PRNT)和免疫荧光抗体试验(IFA)评估免疫应答,并评估全身和局部不良事件。

主要发现

  • 基础三剂后PRNT血清阳转率80.97%,IFA血清阳转率92.81%。
  • 加强后一个月PRNT血清阳性率67.47%,IFA血清阳性率95.68%。
  • 基础三剂接种期间征集性局部不良事件报告率30.50-42.81%,全身不良事件16.67-33.75%;加强后分别为36.57%和21.36%。

临床怎么用

  • 健康成人可按0、1、2、13月程序接种Hantavax®,基础三剂后间隔11个月加强。
  • 免疫原性评估可结合PRNT与IFA,安全性监测需涵盖局部和全身不良事件。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Hemorrhagic fever with renal syndrome is a serious health problem in Eurasian countries. This study aimed to evaluate the immunogenicity and safety of formalin-inactivated Hantaan virus vaccine (Hantavax®) with a 3 + 1 vaccination schedule. METHODS: A phase III, multi-center clinical trial was conducted to evaluate the immunogenicity and safety of Hantavax® (three primary doses and a booster dose schedule at 0, 1, 2 and 13 months) among healthy adults. Immune responses were assessed using the plaque reduction neutralizing antibody test (PRNT) and immunofluorescent antibody assay (IFA). Systemic and local adverse events were assessed. RESULTS: A total of 320 healthy subjects aged ≥19 years were enrolled. Following three primary doses of Hantavax®, the seroconversion rate was 80.97% and 92.81% by PRNT and IFA, respectively. With booster administration, seropositive rates were 67.47% and 95.68% at one-month post-vaccination according to PRNT and IFA, respectively. Solicited local and systemic adverse events were reported in 30.50-42.81% and 16.67-33.75% during the three primary dose vaccination, while those were reported 36.57% and 21.36% after the booster doses. Both local and systemic adverse events did not increase with repeated vaccinations. CONCLUSION: Hantavax® showed a high seroconversion rate after the three-dose priming, and additional dose administration with 11-month interval induced good booster effects. (ClinicalTrials.gov Identifier: NCT02553837).

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Song JY, Jeong HW, Yun JW, et al. Immunogenicity and safety of a modified three-dose priming and booster schedule for the Hantaan virus vaccine (Hantavax): A multi-center phase III clinical trial in healthy adults. Vaccine. 2020. PMID: 33131933. doi:10.1016/j.vaccine.2020.10.035

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。